Objective: Although previous studies have discussed the promise of deep brain stimulation (DBS) as a possible treatment for substance use disorders (SUDs) and collected researcher perspectives on possible ethical issues surrounding it, none have consulted people with SUDs themselves. We addressed this gap by interviewing people with SUDs.
Methods: Participants viewed a short video introducing DBS, followed by a 1.5-hour semistructured interview on their experiences with SUDs and their perspective on DBS as a possible treatment option. Interviews were analyzed by multiple coders who iteratively identified salient themes.
Results: We interviewed 20 people in 12-step-based, inpatient treatment programs (10 [50%] White/Caucasian, 7 Black/African American [35%], 2 Asian [10%], 1 Hispanic/Latino [5%], and 1 [5%] Alaska Native/American Indian; 9 women [45%], 11 men [55%]). Interviewees described a variety of barriers they currently faced through the course of their disease that mirrored barriers often associated with DBS (stigma, invasiveness, maintenance burdens, privacy risks) and thus made them more open to the possibility of DBS as a future treatment option.
Conclusions: Individuals with SUDs gave relatively less weight to surgical risks and clinical burdens associated with DBS than previous surveys of provider attitudes anticipated. These differences derived largely from their experiences living with an often-fatal disease and encountering limitations of current treatment options. These findings support the study of DBS as a treatment option for SUDs, with extensive input from people with SUDs and advocates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417220 | PMC |
http://dx.doi.org/10.1097/ADM.0000000000001150 | DOI Listing |
Mol Genet Metab
December 2024
Department of Molecular Medicine and Medical Biotechnology, Medical School, University of Naples Federico II, 80131 Naples, Italy; CEINGE-Biotecnologie Avanzate Franco Salvatore s.c.ar.l., 80145 Naples, Italy. Electronic address:
Background: Newborn screening (NBS) is a simple, non-invasive test that allows for the early identification of genetic diseases within the first days of a newborn's life. The aim of NBS is to detect potentially fatal or disabling conditions in newborns as early as possible, before the onset of disease symptoms. Early diagnosis enables timely treatments and improves the quality of life for affected patients.
View Article and Find Full Text PDFAsian J Psychiatr
December 2024
OCD Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), India.
Deep Brain Stimulation is a form of neurostimulation where electrical stimulation is delivered via intracranial electrodes over specific subcortical targets. It has been increasingly used as an alternative to ablative procedures for psychiatric disorders refractory to standard treatments. This review describes the common psychiatric indications for DBS, the current evidence base, putative mechanisms, and future directions.
View Article and Find Full Text PDFNoise Health
January 2025
K M Shah Dental College and Hospital, Sumandeep Vidyapeeth deemed to be University, Waghodia, Vadodara - 391760, India.
Background: Noise sources in paediatric dental offices include machinery and children's cries and screams. Although the presence of occupational noise-induced hearing loss (ONIHL) among dental operators is established, preventive measures such as ear protection devices (EPDs) are not frequently employed as prophylactic intervention. The primary aim of this study was to quantitatively assess the noise levels in paediatric dental clinics and to qualitatively evaluate the operators' perception of noise with and without the use of EPDs.
View Article and Find Full Text PDFBackground: An advantage of blood-based biomarkers of Alzheimer's disease (AD) is that collection is easily repeatable and minimally invasive. Repeated biomarker measurements provide greater sensitivity for detecting within-person change, which in clinical trials can allow for reductions in sample sizes required to detect treatment effects and shorten trial periods. We validated Dried Blood Spots (DBS) as a novel matrix for measuring blood biomarkers of AD, as collection is easily repeatable, less burdensome for participants, and more economical than phlebotomy, and shipment and storage are simplified.
View Article and Find Full Text PDFNeurol Neurochir Pol
January 2025
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Introduction: In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.
Aim Of Study: The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!